Literature DB >> 1590700

Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits.

M S Rouse1, B M Tallan, J M Steckelberg, N K Henry, W R Wilson.   

Abstract

Cilofungin has potent in vitro activity against Candida albicans, but previous in vivo models using twice daily intermittent dosing regimens have not consistently demonstrated in vivo efficacy. Because of the pharmacokinetics of cilofungin in rabbits, it has been suggested that administration by continuous intravenous infusion might be more effective. We compared the in vivo efficacy of continuous intravenous infusion of cilofungin with that of amphotericin B in a rabbit model of disseminated candidiasis. Cilofungin prepared as previously described in phosphate-buffered 33% polyethylene glycol was lethal to infected rabbits in this model, as was phosphate-buffered 33% polyethylene glycol alone. In contrast, cilofungin in 26% polyethylene glycol and sterile water administered by continuous intravenous infusion was tolerated by rabbits, was significantly more effective than amphotericin therapy in reducing candida colony counts in kidney tissue, and was as effective as amphotericin therapy in lung and spleen tissue and in cardiac valvular vegetations. The dosage regimen and diluent used in some previous studies may have adversely affected outcome of treatment with cilofungin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590700      PMCID: PMC189225          DOI: 10.1128/AAC.36.1.56

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits.

Authors:  J W Lee; P Kelly; J Lecciones; D Coleman; R Gordee; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis.

Authors:  C J Morrison; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species.

Authors:  A Huang; F Edwards; E M Bernard; D Armstrong; H J Schmitt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

4.  Comparison of cilofungin and amphotericin B for therapy of murine candidiasis.

Authors:  K R Smith; K M Lank; C G Cobbs; G A Cloud; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Treatment of experimental disseminated candidiasis with cilofungin.

Authors:  J R Perfect; M M Hobbs; K A Wright; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens.

Authors:  L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  In vitro and in vivo anti-Candida activity and toxicology of LY121019.

Authors:  R S Gordee; D J Zeckner; L F Ellis; A L Thakkar; L C Howard
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

8.  Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.

Authors:  T J Walsh; J W Lee; P Kelly; J Bacher; J Lecciones; V Thomas; C Lyman; D Coleman; R Gordee; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity.

Authors:  C S Taft; T Stark; C P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

10.  Experimental endocarditis. IV. Tricuspid and aortic valve infection with Candida albicans in rabbits.

Authors:  L R Freedman; M L Johnson
Journal:  Yale J Biol Med       Date:  1972-04
View more
  6 in total

1.  Treatment of murine disseminated candidiasis with L-743,872.

Authors:  J R Graybill; L K Najvar; M F Luther; A W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors:  R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 5.  Compounds active against cell walls of medically important fungi.

Authors:  R F Hector
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

6.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.